Catching respiratory illnesses early is crucial to prevent their spread and get proper treatment. This study explored the potential of using wearable sensors and self-reported symptoms to prompt people to test themselves for common viruses at home. We found that this approach holds promise for early detection, but also identified areas for improvement before widespread use.
Quickly identifying respiratory infections like COVID-19 and RSV is key to controlling their spread. Traditionally, this involves visiting a doctor's office or clinic. However, a new approach is gaining traction: home testing. This study investigated whether wearable sensors and self-reported symptoms could trigger timely home testing for these viruses.
We conducted a decentralized, randomized controlled trial involving 450 participants in the US. Participants were randomly assigned to one of three groups:
Group 1: Received a wearable sensor (Fitbit Sense) and could be prompted to take home tests based on changes in their physiological data or self-reported symptoms.
Group 2: Received a wearable sensor and home tests, triggered only by symptoms.
Group 3: Control group with no wearable sensors or home tests.
The primary goal was to assess the feasibility of prompting home testing based on wearable data or symptoms and to measure how many participants actually used the home tests.
The trial successfully recruited and randomized participants.
Over half (52%) were from underrepresented groups in research.
Among those who received home tests (Groups 1 and 2), 39% were prompted to test.
More prompts were triggered by symptoms (68%) than wearable data (32%).
Out of those prompted, 52% successfully performed the home test.
Of those tested, 31% were positive for a virus (all SARS-CoV-2).
Notably, there were no adverse events related to the testing approach.
This study demonstrates the early feasibility of a program prompting home testing for respiratory viruses based on both symptoms and wearable data. However, areas for improvement were identified:
Wearable sensors need better refinement to trigger testing more effectively.
Strategies to increase participation rates in-home testing are necessary.
This study paves the way for utilizing wearable sensors and home testing to identify respiratory viruses. Further research will focus on optimizing technology and participant engagement to facilitate wider implementation of this promising approach.
Quer G, Coughlin E, Villacian J, et al. Feasibility of wearable sensor signals and self-reported symptoms to prompt at-home testing for acute respiratory viruses in the USA (DETECT-AHEAD): a decentralized, randomized controlled trial. Lancet Digit Health. 2024;6(8):e546-e554. doi:10.1016/S2589-7500(24)00096-7
1.
New surgical method shows promising results for cervical cancer treatment
2.
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth
3.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
4.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
5.
Can Prior Authorization Be Better With Artificial Intelligence?
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Public Health Strategies for Improving Cancer Survivorship Support Systems
3.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
4.
Treating Methemoglobinemia: What You Need to Know Now!
5.
Red Cell Deformability as a Target in Critical Illness
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
2.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation